NTLA today
$11.41+$0.24 (+2.15%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourLeaning Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $18.48
Key levels
Resistance$13.94
Resistance$11.99
Support$10.87
Support$9.85
Latest news & SEC filings
AnalystJ.P. Morgan revises price target on Intellia Therapeutics
EarningsIntellia Therapeutics Reports Third Quarter 2026 Financial Results
All NTLA news →About Intellia Therapeutics
Intellia Therapeutics is a biopharmaceutical company that develops treatments using CRISPR gene editing and lipid nanoparticle delivery. Its main product candidates are lonvoguran ziclumeran for hereditary angioedema and nexiguran ziclumeran for transthyretin amyloidosis. The company operates in the United States and collaborates with Regeneron Pharmaceuticals.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Intellia Therapeutics, Inc. (NTLA)
What Is the Price Target for NTLA?
SEPT Low Target
$8.00
SEPT Mid Target
$16.00
SEPT High Target
$49.00
Analyst Consensus
$16.00
Is NTLA a Buy or Sell Right Now?
Thesis
- •Revenue growing 16.9% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 3 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NTLA.
Start Free Trial →Is NTLA Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$14.83
27
Moat Score
NONE
3/9
Piotroski Score
-1.0
Altman Z-Score
What Is Smart Money Doing with NTLA?
Insider Signal
SELLING
0 buys / 6 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| LEONARD JOHN M | director officer | Sale | 9,000 | $108K | Nov 2, 2026 |
| Marantz Jing L. | officer | Buy | 199,822 | - | Oct 26, 2026 |
| Dube Michael P | officer | Sale | 1,864 | $23K | Oct 2, 2026 |
| LEONARD JOHN M | director officer | Sale | 2,785 | $36K | Aug 21, 2026 |
| LEONARD JOHN M | director officer | Sale | 19,890 | $251K | Aug 20, 2026 |
| Dulac Edward J III | officer | Sale | 8,111 | $91K | Jul 22, 2026 |
| Verwiel Frank | director | Buy | 9,200 | - | Jun 9, 2026 |
| Goff Brian | director | Buy | 9,200 | - | Jun 9, 2026 |
| Cohen Fred E | director | Buy | 9,200 | - | Jun 9, 2026 |
| CHASE WILLIAM J | director | Buy | 9,200 | - | Jun 9, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →NTLA Growth Story
Revenue YoY
16.9%
3yr Revenue CAGR
9.1%
EPS Growth YoY
27.43%
FCF Growth YoY
-11.6%
Revenue Trend
ACCELERATING
Dark Pool Trades for NTLA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for NTLA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 09:00:08 | $11.37 | 1,800 | $$20K | SELL |
| 21:26:17 | $11.41 | 58,312 | $$665K | SELL |
| 21:00:56 | $11.41 | 2,170 | $$25K | SELL |
| 21:00:28 | $11.41 | 6,773 | $$77K | SELL |
| 21:00:28 | $11.41 | 1,608 | $$18K | SELL |
5 dark pool trades shown · $$806K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for NTLA
PREVIEWSEPT Investing provides real-time options flow tracking for NTLA, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $42 | Jan 21 | 436 | $$90 | 1 | SWEEP |
| CALL | $11 | Jan 15 | 65 | $$21.0K | 100 | BLOCK |
| CALL | $10 | Apr 16 | 156 | $$32.0K | 100 | BLOCK |
| CALL | $10 | Apr 16 | 156 | $$1550 | 5 | SWEEP |
| CALL | $10 | Apr 16 | 156 | $$1550 | 5 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Intellia Therapeutics, Inc. (NTLA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NTLA — frequently asked questions
What is NTLA stock price today?
Intellia Therapeutics, Inc. (NTLA) is at $11.41, up 2.15% (+$0.24) at the Nov 11, 2026 close.
Why is NTLA stock moving today?
Latest NTLA news — Nov 10, 2026: J.P. Morgan revises price target on Intellia Therapeutics · Nov 5, 2026: Intellia Therapeutics Reports Third Quarter 2026 Financial Results
Why did NTLA stock move on Nov 5, 2026?
Intellia Therapeutics shares fell 9.46% to close at $11.10 after the company reported third-quarter 2026 results featuring a wider-than-expected per-share loss of $0.91 versus the $0.80 consensus and revenue of $7.163 million, well below the $10.461 million analysts expected. The stock traded between a high of $12.26 and a low of $10.87 on heavy volume of 7,412,730 shares.
What is the NTLA price target?
The average analyst price target for NTLA is $16.00, ranging from $8 to $49, based on 14 analysts. Latest: Barclays initiates on Oct 6, 2026.
What do analysts rate NTLA?
Analyst ratings for NTLA: 1 Buy, 19 Hold, 2 Sell — consensus Hold.
Did NTLA beat earnings?
NTLA last reported on Nov 5, 2026: EPS -$0.91 vs -$0.80 expected — a miss of 14.2%.
Does NTLA pay a dividend?
NTLA does not currently pay a dividend.
How much debt does NTLA have?
Intellia Therapeutics, Inc. reported $74M of debt and $156M of cash (Sep 30, 2026).
What are NTLA support and resistance levels?
Support: $10.87, $9.85, $8.94. Resistance: $11.99, $13.94, $15.51.
What are insiders doing with NTLA?
Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.
What is the latest news on NTLA?
Nov 10, 2026: J.P. Morgan revises price target on Intellia Therapeutics · Nov 5, 2026: Intellia Therapeutics Reports Third Quarter 2026 Financial Results